Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

CEO: New JV could be “very significant” for Horizon Discovery

Horizon Discovery (LON:HZD) chief executive Darrin Disley talks to Proactive Investors on the new joint venture it has formed with UK based biotech Centauri Therapeutics to target an immuno-oncology market currently worth £25bn a year.

A relatively young market, the first wave of treatments “are already multi-billion dollar drugs,” Disley says, adding that the immune-oncology space is expected to double over the next five to ten years on the back of the new class of immunotherapy.

Under the terms of the deal with Centauri, Horizon will out-license certain intellectual property (IP) relating to its translational genomics and drug discovery platforms, and will invest up to £5.3 million over two tranches.

 
Meet Allergy Therapeutics plc, Cello Group plc, Sphere Medical Holding PLC and ValiRx Plc at our event, London, 06 October 2016. Register here »
View full HZD profile

Horizon Discovery Group PLC Timeline

Newswire
September 20 2016
Big Picture
September 13 2016
Newswire
September 06 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.